



Tight Control in Type 2 Diabetes: More Harm than Good? References

1. Accord Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med*. 2011;364(9):818-828.
2. Advance Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358(24):2560-2572.
3. Ahmed MA, Muntingh G, Rheeder P. Vitamin B12 deficiency in metformin-treated type-2 diabetes patients, prevalence and association with peripheral neuropathy. *BMC pharmacology & toxicology*. 2016;17(1):44.
4. American Diabetes Association. Standards of Medical Care. *Diabetes Care* 2017; https://professional.diabetes.org/sites/professional.diabetes.org/files/media/dc_40_s1_final.pdf.
5. Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. *Diabetes Care*. 2006;29(8):1777-1783.
6. Center for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. 2011; <http://www.familydocs.org/f/CDC%20Diabetes%20fact%20sheet-2011.pdf>.
7. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. *Lancet*. 2010;375(9713):481-489.
8. de Groot-Kamphuis DM, van Dijk PR, Groenier KH, Houweling ST, Bilo HJ, Kleefstra N. Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. *The Netherlands journal of medicine*. 2013;71(7):386-390.
9. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360(2):129-139.
10. Finucane TE. "Tight control" in geriatrics: the emperor wears a thong. *J Am Geriatr Soc*. 2012;60(8):1571-1575.
11. Food and Drug Administration. Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. 2008; <https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf>.
12. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. *JAMA internal medicine*. 2014;174(5):678-686.
13. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. *Diabetes Care*. 2010;33(7):1674-1685.
14. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. *BMJ*. 2011;343:d6898.
15. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2013(11):CD008143.
16. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *Br J Clin Pharmacol*. 1999;48(5):643-648.

17. Lipska KJ, Krumholz HM. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? *JAMA*. 2017;317(10):1017-1018.
18. Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. *PLoS One*. 2014;9(6):e100379.
19. Osler W. Vol 2, Part 3: Oxford Medicine; 1909:245.
20. Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Clinical Guidelines Committee of the American College of P. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med*. 2017;166(4):279-290.
21. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2005(3):CD002966.
22. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2010(1):CD002967.
23. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2006(3):CD002968.
24. Wood S, Eckert J, Hogenmiller A, Sundaramoorthy D, Cook S, Fugh-Berman A. Impacts of Pharmaceutical Marketing on Healthcare in the District of Columbia. 2016; <https://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/Impacts%20Report%202016%20-%20Diabetes.pdf>.